CL2023003357A1 - Régimen de dosis para terapia combinada dirigida a dll3 y pd-1 - Google Patents

Régimen de dosis para terapia combinada dirigida a dll3 y pd-1

Info

Publication number
CL2023003357A1
CL2023003357A1 CL2023003357A CL2023003357A CL2023003357A1 CL 2023003357 A1 CL2023003357 A1 CL 2023003357A1 CL 2023003357 A CL2023003357 A CL 2023003357A CL 2023003357 A CL2023003357 A CL 2023003357A CL 2023003357 A1 CL2023003357 A1 CL 2023003357A1
Authority
CL
Chile
Prior art keywords
combination therapy
dosage regimen
dll3
therapy targeting
targeting dll3
Prior art date
Application number
CL2023003357A
Other languages
English (en)
Spanish (es)
Inventor
Hashemi Sadraei Nooshin
SHETTY Aditya
MINOCHA Mukul
Damiette SMIT Marie-Ann
Wong Hansen
Roychoudhury Siddhartha
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2023003357A1 publication Critical patent/CL2023003357A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2023003357A 2021-05-10 2023-11-10 Régimen de dosis para terapia combinada dirigida a dll3 y pd-1 CL2023003357A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163186569P 2021-05-10 2021-05-10

Publications (1)

Publication Number Publication Date
CL2023003357A1 true CL2023003357A1 (es) 2024-06-07

Family

ID=84029376

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003357A CL2023003357A1 (es) 2021-05-10 2023-11-10 Régimen de dosis para terapia combinada dirigida a dll3 y pd-1

Country Status (12)

Country Link
US (1) US20240317856A1 (https=)
EP (1) EP4337252A4 (https=)
JP (1) JP2024518947A (https=)
KR (1) KR20240006585A (https=)
CN (1) CN117377488A (https=)
AU (1) AU2022273509A1 (https=)
CA (1) CA3217141A1 (https=)
CL (1) CL2023003357A1 (https=)
IL (1) IL307646A (https=)
MX (1) MX2023013227A (https=)
TW (1) TW202309092A (https=)
WO (1) WO2022240688A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
JP2025508786A (ja) * 2022-02-23 2025-04-10 アムジェン インコーポレイテッド Ｄｌｌ３を標的とする癌治療
EP4630458A2 (en) * 2022-12-08 2025-10-15 Amgen Inc. Methods for treating dll3-expressing cancer
TW202509075A (zh) * 2023-05-19 2025-03-01 德商百靈佳殷格翰國際股份有限公司 T細胞銜接蛋白治療癌症之用途
CN120168667B (zh) * 2025-03-18 2026-04-14 中国科学院近代物理研究所 一种多肽在制备dll3过度表达的肿瘤的特异性靶向分子探针中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
CN108136015A (zh) * 2015-08-20 2018-06-08 艾伯维施特姆森特克斯有限责任公司 抗dll3抗体药物缀合物以及使用方法
CA3095920A1 (en) * 2018-04-10 2019-10-17 Amgen Inc. Chimeric receptors to dll3 and methods of use thereof
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白

Also Published As

Publication number Publication date
EP4337252A1 (en) 2024-03-20
MX2023013227A (es) 2024-01-29
TW202309092A (zh) 2023-03-01
CN117377488A (zh) 2024-01-09
CA3217141A1 (en) 2022-11-17
US20240317856A1 (en) 2024-09-26
JP2024518947A (ja) 2024-05-08
IL307646A (en) 2023-12-01
AU2022273509A1 (en) 2023-10-19
WO2022240688A1 (en) 2022-11-17
KR20240006585A (ko) 2024-01-15
EP4337252A4 (en) 2025-04-23

Similar Documents

Publication Publication Date Title
CL2023003357A1 (es) Régimen de dosis para terapia combinada dirigida a dll3 y pd-1
MX2022005596A (es) Regimen de dosificacion para agentes anti-dll3.
CL2020002945A1 (es) Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t
DOP2023000107A (es) Compuesto de heteroarilcarboxamida
CL2024002529A1 (es) Tratamiento del cáncer dirigido a dll3
CO2017011536A2 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo
AR101504A1 (es) Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
MX2021001083A (es) Regimen posologico para anticuerpos biespecificos contra bcma-cd3.
MX388093B (es) Dosis y regimen para inhibidores de la interaccion hdm2-p53.
CL2020000271A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr y un inhibidor de quinasa dependiente de ciclina.
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
CO2023009635A2 (es) Conjugado de anticuerpo anti-dll3-fármaco
MX2024003918A (es) Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer.
MX2023004554A (es) Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs.
CL2024001870A1 (es) Paradigma de tratamiento para una terapia con anticuerpos anti-cd19.
MX2025001181A (es) Regimenes de dosificacion que comprenden un inhibidor kat6 para el tratamiento de cancer
ECSP23076276A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
CL2025002930A1 (es) Programa de dosificación de un inhibidor de her.2
CR20220127A (es) Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
MX2022005628A (es) Regimen de dosificacion para agentes anti-bcma.
JOP20250015A1 (ar) تركيبة صيدلانية للأجسام المضادة ضد cd20 واستخداماتها
CO2021014370A2 (es) Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyen
BR112022018161A2 (pt) Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer
MX2024012368A (es) Terapia combinada para el tratamiento del cancer